BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

...Partners and Samsara Capital, Chinook Therapeutics Inc. brings to the union preclinical rare disease therapy CHK-336...
...Chinook has not yet named the rare disease for which it hopes to test CHK-336...
...STING (TMEM173) - Transmembrane protein 173 Paul Bonanos, Associate Editor Xinlay, atrasentan (ABT-627) APRIL (BION-1301) Chinook Therapeutics Inc. Aduro Biotech Inc. CHK-336...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 17, 2019
Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support,...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
BioCentury | May 6, 2019
Distillery Therapeutics

PARG inhibition for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Cell culture experiments suggest inhibiting PARG alone or in combination with Chk1 inhibitors could help treat ovarian cancer. In three human ovarian cancer cell lines, a tool compound PARG...
BioCentury | Apr 16, 2019
Preclinical News

Mounting a mitochondrial attack to starve the inflammasome

...see “Novintum: Bugging Cancer” ; “A Mitochondrial Shield From Cell Death” ). Targets: CHKA - Choline kinase...
...family 44 member 1 Allison Johnson, Staff Writer Mission Therapeutics Ltd. Novintum Bioscience Ltd. Rheostat Therapeutics University of California San Diego Choline kinase...
BioCentury | Mar 15, 2019
Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
Items per page:
1 - 10 of 84